Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

Blood (2024) 144 (Supplement 1): 303.

https://doi.org/10.1182/blood-2024-209378

Published: 2024

Journal Articles

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Blood (2024) 144 (Supplement 1): 1318.

https://doi.org/10.1182/blood-2024-208841

Published: 2024

Journal Articles

Full CD34 Donor Chimerism Following CD34 Chimerism Directed Donor Lymphocyte Infusion Results in Reduced Relapse and Superior Overall Survival Compared with Mixed Chimerism Status in Allogeneic Haemopoietic Stem Cell Transplant Recipients

Joanne BL Tan, David J. Curtis, Jenny Muirhead, Michael Swain, Shaun Fleming, BIanca Cirone, Maureen O'Brien, Shu Min Wong, Shafqat Inam, Sushrut S. Patil, Andrew Spencer

Blood (2023) 142 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2023-185307

Published: 2023

Journal Articles

Haploidentical Donor Transplants with Cytokine Release Syndrome Have Increased Risk of Clinically Significant Early CMV Reactivation Compared with Matched Donor Transplants Receiving Post-Transplant Cyclophosphamide

James Schwarer, Joanne BL Tan, BIanca Cirone, Lily Rush, Jenny Muirhead, Shu Min Wong, Shafqat Inam, Shaun Fleming, Sushrut S. Patil, C. Orla Morrissey, John Coutsouvelis, Andrew Spencer, David J. Curtis

Blood (2023) 142 (Supplement 1): 6955.

https://doi.org/10.1182/blood-2023-188294

Published: 2023

Journal Articles

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Eliza Hawkes, Katharine L. Lewis, Nicole Wong Doo, Sushrut S. Patil, Hari P. Miskin, Peter Sportelli, Kathryn S. Kolibaba, Emmanuel Normant, Tejasvi Turpuseema, Chan Y. Cheah

Blood (2022) 140 (Supplement 1): 6599–6601.

https://doi.org/10.1182/blood-2022-169171

Published: 2022

Journal Articles

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia - the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

Blood (2022) 140 (Supplement 1): 2931–2932.

https://doi.org/10.1182/blood-2022-168963

Published: 2022

Journal Articles

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Kirsty M Sharplin, MBBS, David Ritchie, MB ChB, PhD FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Shyam Panicker, MBBS,MDMRCP,FRACP,FRCPA, Glen A Kennedy, MBBS FRACP FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Julian Cooney, FRACP,FRCPA,MBBS,, Richard Doocey, MB ChB, FRACP, FRCPA, Leanne Berkahn, MD, Sam Milliken, MBBS, FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Peter G Bardy, MBBS, FRACP, FRCPA, FRCPath, Andrew Spencer, David J. Curtis, MBBS,PhD, Sushrut S. Patil, Stephen R Larsen, MBBS PhDFRACP FRCPA, Travis Perera, MB ChB, FRACP, FRCPA, Andrew Butler, MB ChB(Edin), MRCP, MRCPath, Matthew Greenwood, MBBS, FRACP, FRCPA, Anne-Marie Watson, FRACP, FRCPA, MBBS, Hock Choong Lai, MBBS, FRACP, FRCPA, Eric Wong, MDPhD FRACP, FRCPA, Steven Tran, BEng MBiomedE, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-138684

Published: 2020

Journal Articles

Peripheral Blood CD34 + Donor Chimerism Is Superior to CD3 + Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies

Tongted Das, PhD, Daniel North, Shaun Fleming, David Kliman, Andrew Spencer, Andrew H. Wei, Sushrut S. Patil, Jacueline Widjaja, Maureen O'Brien, David J. Curtis, MBBS,PhD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-143465

Published: 2020

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

Hypercalcaemia at Diagnosis Is an Independent Predictor of Poor Survival in Diffuse Large B-Cell Lymphoma

Michael P Gilbertson, MBBS,FRACP,FRCPA, Maciej Tatarczuch, BMBS, FRACP, FRCPA, Ashish Kumar Panigrahi, MBBS, Samuel Robinson, David Wong, PhD, Pasquale L. Fedele, FRACP, FRCPA, Gareth Gregory, MBBS,PhDFRACP,FRCPA, George Grigoriadis, MBBS PhDFRACP FRCPA, Michael S. Low, MBBS, Sushrut S. Patil, FRACP, FRCPA, Sumita Ratnasingham, FRACP, FRCPA, Jake Shortt, MBBS PhDFRACP FRCPA, Fathima Shahla Vilcassim, MBBS, FRACP, FRCPA, Jonathan Wong, MBBS, Sophie Lee, FRACP, FRCPA, PhD, Duncan P. Carradice, MBBS, FRCPA, FRACP, William E. P. Renwick, MBBS, FRACP, FRCPA, Stephen Opat, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1568.

https://doi.org/10.1182/blood.V130.Suppl_1.1568.1568

Published: 2017

Journal Articles

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S. Tam, MD, Hang Quach, MBBS, MD, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, MD FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, Richard Eek, MBCHB, Nicholas Wickham, FRCPA,FRACP,FRCPath, Sushrut S. Patil, FRACP, FRCPA, Jane Huang, MD, Xiaoping Zhang, MD PhD, Lai Wang, PhD, Eric Hedrick, MD, William Novotny, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 1745.

https://doi.org/10.1182/blood.V130.Suppl_1.1745.1745

Published: 2017

Journal Articles

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

Shaun Fleming, MBBS(Hons) FRACP FRCPA, Nik Cummings, Tongted Das, Adam Ivey, BSc, MSc, PhD, Julie McManus, Sharon Avery, MBBS, FRACP, FRCPA, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, David J. Curtis, MBBS,PhD FRACP, FRCPA, Andrew Spencer, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 2674.

https://doi.org/10.1182/blood.V130.Suppl_1.2674.2674

Published: 2017

Journal Articles

Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy

Sumita Ratnasingam, MBBS, Michael Gilbertson, Zoe McQuilten, MBBS, Kay T Htun, George Grigoriadis, MBBS, PhD BSc, Swe Myo Htet, MBBS, Philip Campbell, MBBS, FRACP, FRCPA, Khai Li Chai, MBBS, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Sushrut S. Patil, FRACP, FRCPA, Jake Shortt, MD, Stephen Opat, MD

Blood (2016) 128 (22): 2965.

https://doi.org/10.1182/blood.V128.22.2965.2965

Published: 2016

Journal Articles

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

Anish Puliyayil Nair, MD DM, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Jenny Muirhead, Andrew Spencer

Blood (2015) 126 (23): 5543.

https://doi.org/10.1182/blood.V126.23.5543.5543

Published: 2015

Journal Articles

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Anish Puliyayil Nair, MD DM, Patricia A. Walker, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Krystal Bergin, MBBS, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Jenny Muirhead, Tongted Phomoonna, Daniela Klarica, RN, Andrew Spencer

Blood (2015) 126 (23): 2030.

https://doi.org/10.1182/blood.V126.23.2030.2030

Published: 2015

Journal Articles

The Effect of Granulocyte-Colony-Stimulating Factor (G-CSF) on T Cell Polarization in Vitro : A Direct Comparison Between Nivestim® and Neupogen®

Nicole Mifsud, Amina Ismail, Elisha de Valle, Andrew Spencer, MD, Sushrut S. Patil, FRACP FRCPA, George Grigoriadis, MBBS, PhD BSc, Raffi Gugasyan

Blood (2014) 124 (21): 5803.

https://doi.org/10.1182/blood.V124.21.5803.5803

Published: 2014

Journal Articles

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Philip Campbell, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Andrew H Wei, MBBS, PhD, Anna Kalff, MBBS, FRACP, FRCPA, Jenny Muirhead, Andrew Spencer, MD

Blood (2013) 122 (21): 2128.

https://doi.org/10.1182/blood.V122.21.2128.2128

Published: 2013

Journal Articles

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Philip Campbell, MBBS, FRACP, FRCPA, Tongted Das, David Kipp, Patricia A. Walker, MBBS, FRACP, FRCPA, Jenny Muirhead, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Anna Kalff, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2013) 122 (21): 2129.

https://doi.org/10.1182/blood.V122.21.2129.2129

Published: 2013

Journal Articles

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Anthony P. Schwarer, MD, Elchanan H. Januszewicz, MBBS, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Wai Khoon Ho, MBBS FRACP FRCPA, Constantine S. Tam, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2011) 118 (21): 3625.

https://doi.org/10.1182/blood.V118.21.3625.3625

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD

Blood (2011) 118 (21): 1529.

https://doi.org/10.1182/blood.V118.21.1529.1529

Published: 2011

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve Severe Aplastic Anemia: Results of the Diaamond-Ava-First Trial

Cellular and Cell-Free Genomic Characterization of Patients Receiving Avatrombopag and Immunosuppressive Therapy for Treatment-Naïve Severe Aplastic Anemia

Full CD34 Donor Chimerism Following CD34 Chimerism Directed Donor Lymphocyte Infusion Results in Reduced Relapse and Superior Overall Survival Compared with Mixed Chimerism Status in Allogeneic Haemopoietic Stem Cell Transplant Recipients

Haploidentical Donor Transplants with Cytokine Release Syndrome Have Increased Risk of Clinically Significant Early CMV Reactivation Compared with Matched Donor Transplants Receiving Post-Transplant Cyclophosphamide

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia - the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation

Peripheral Blood CD34 + Donor Chimerism Is Superior to CD3 + Donor Chimerism for Predicting Relapse Following Allogeneic Stem Cell Transplantation for Myeloid Malignancies

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Hypercalcaemia at Diagnosis Is an Independent Predictor of Poor Survival in Diffuse Large B-Cell Lymphoma

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

Improved Survival of Older Patients with Mantle Cell Lymphoma (MCL) with Front-Line Cytarabine-Based Immunochemotherapy

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

The Effect of Granulocyte-Colony-Stimulating Factor (G-CSF) on T Cell Polarization in Vitro : A Direct Comparison Between Nivestim® and Neupogen®

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only